Oxidative Medicine and Cellular Longevity / 2018 / Article / Tab 1

Review Article

Anticancer Properties of Graviola (Annona muricata): A Comprehensive Mechanistic Review

Table 1

Different solvent extracts of A. muricata and their reported anticancer activities.

Extract (solvent)Cancers (cell lines)

n-HexaneCervical (HeLa) cancer [37]
ChloroformCervical (HeLa) cancer [37]
PentaneMelanoma (A375) cancer [36]
n-Butanolic(MDA-MB-435S) cancer [89], now known as a melanoma cell line [90]
DMSOPancreatic (Capan-1 [92], FG/COLO357, and CD18/HPAF [28]) cancer
Fungal strainBreast (MCF-7) [38], colorectal (HTC-8) [38], lung cancer (A549) [38], hepatic (Bel-7402) [38], gastric (BGC-823) [38], and ovarian (A2780) [38] cancers
H2OSquamous cell carcinoma (SCC-25) [91], melanoma (A375) [36], prostate (PC-3) [21], pancreatic (CD18/HPAF) [28], and breast cancer patients [118]
HexaneBreast (MCF-7 and MDA-MB-231) [31], colorectal (HT-29 and HCT-116) [26], lung cancer (A549) [31], leukemic (U-937) [33, 46], pancreatic (Capan-1) [92], and hepatic (Hep G2) [31] cancers
Ethyl acetateBreast (MCF-7 and MDA-MB-231) [31], colorectal (HT-29 and HCT-116) [25], lung (A549) [31], leukemic (U-937) [33, 46, 131], hepatic (Hep G2) [31], and cervical (HeLa) [37] cancers.
EthanolEhrlich ascite carcinoma (EACC) [93], breast (MCF-7 [45], MDA-MB-231-BCRP clone 23 [77, 139], T47D [22], MDA and SKBR3 [93]), colorectal [20] [140] (COLO-205 and DLD-1) [94], lung (H-460) [45, 95], leukemic (K562 [19] [96], ECV304 [96] and HL-60 [27]), stomach (C-678) [95], melanoma (A375) [36], skin [141], glioma (SF-268) [45], and cervical (HeLa) [37] cancers
MethanolBreast (MCF-7 and MDA-MB-231 [31], MDA-MB-231-pcDNA3, and MDA-MB-231-BCRP clone 23 [24]), colorectal (HT-29 and HCT-116 [26], HCT116 (p53+/+), and HCT116 (p53/) [24]), lung (A549 [31] and NCI-H292 [113]), leukemic (U-937 [33, 46], CCRF-CEM, and CEM/ADR5000 [24]), hepatic (Hep G2 [24, 31] and Hep 2,2,15 [31]), glioma (U87MG and U87MG.ΔEGFR) [24], and laryngeal (currently cervical HeLa; Hep-2) [113] cancers

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.